• Marwan Bendixen posted an update 2 months, 2 weeks ago

    HCC developed in 339 patients (mean follow-up 7.0 years), with cumulative incidence rates at 3, 5 and 10 years of 12.7, 24.5 and 41.9% in the anti-HBc positive group and 10.6, 17.7 and 33.4% in the negative group, respectively (P = 0.005). However, anti-HBc seropositivity did not reach statistical significance in multivariate analysis including age and gender (hazard ratio, 1.06; 95% CI, 0.85–1.31; P = 0.63). Anti-HBc positivity and HCC incidence were confounded by male gender and older age. “”Literature shows that proteins involved in metabolism of connective tissue as tissue inhibitor of metalloproteinases 1 (TIMP-1) and matrix metalloproteinase 2 (MMP-2) among others, are detected in circulation and may be useful as serum markers of fibrosis during chronic HCV infection (1, 2). Aim of the study was to assess Quizartinib molecular weight the impact of therapy with pegylated interferon alpha and ribavirin on plasma TIMP-1/MMP-2 ratio depending on the sustained virological response (SVR) achieved and its usefulness in monitoring the effects of antiviral treatment. Study group included 54 chronic hepatitis C (CHC) patients (25 females, 29 males), aged from 21 to 57 years (mean 37 years), infected with genotype 1 and homogenic liver biopsy Metavir results. Treatment with pegylated IFN alpha and ribavirin according to guidelines was conducted for 48 weeks. Plasma TIMP-1 and MMP-2 concentrations were determined by enzyme immunoassay method using ready kit Human TIMP-1 Instant ELISA and Human/Mouse/Rat MMP-2 (total) Immunoassay twice at the beginning of therapy and 6 months after treatment. TIMP-1/MMP-2 ratio was calculated for each probe. Results were analyzed according to SVR achievement at 6 months after completion of therapy. In the group of 26 (48%) patients with SVR the TIMP-1/MMP-2 ratio decreased significantly after treatment (p < 0.001). In 28 (52%) patients who did not achieve SVR, the TIMP-1/MMP-2 ratio obtained after treatment was significantly higher than the values at the beginning of therapy (p < 0.05). Comparative analysis of results in groups of patients according to SVR revealed that there were no statistically significant differences in plasma TIMP-1/MMP-2 ratio at the beginning of therapy but 6 months after cessation of treatment TIMP-1/MMP-2 ratio was significantly lower in patients with a virologic response after treatment compared with no SVR group (p < 0.001). The study results showed that the balance between concentration of TIMP-1 and MMP-2 in plasma may be useful in assessing effects of antiviral treatment and predicting fibrosis in patients with CHC treated with antiviral therapy (3–12). 1. Arai M, Niioka M, Maruyama K, et al.: Changes in serum levels of metalloproteinases and their inhibitors by treatment of chronic hepatitis C with interferon. Dig Dis Sci 1996, 41(5): 995–1000. 2. Ninomiya T, Yoon S, Nagano H, et al.